EL7.AI
StocksMedium•15 October 2026•
4 min read

Recursion Prices Share Offering of About $200 Million to Fund Drug Development

Key Facts

1Recursion expects gross proceeds of about $200 million before deducting underwriting commissions and estimated expenses.
2The prospectus estimated net proceeds of about $187.2 million after deducting expected commissions and expenses.
3The company expects available cash, including the offering proceeds, to fund operating expenses and capital requirements into 2029.
4The median reduction in polyp burden with REC-4881 was about 47% after 12 weeks of treatment.
5Recursion became entitled to a $10 million milestone payment after Sanofi exercised its option on the drug candidate.

Recursion priced an underwritten share offering with expected gross proceeds of about $200 million, according to its October 2026 offering pricing statement, to fund its drug development programs and technology platform. The offering comprises 61,540,000 shares of Class A common stock at $3.25 per share. The company is selling all the shares offered, with gross proceeds calculated before deducting underwriting commissions and estimated expenses payable by the company. The final prospectus, filed with the U.S. Securities and Exchange Commission, estimated net proceeds of about $187.2 million after those deductions. New investors face immediate dilution of $2.21 per share in net tangible book value, according to the illustrative calculation in the prospectus.

Recursion preliminarily estimated its cash, cash equivalents and restricted cash at about $561 million as of September 30, 2026, according to its SEC disclosure. It expected available cash, including the offering proceeds, to fund operating expenses and capital requirements into 2029. In its second-quarter results update published in August, it had expected funding to last into early 2028 without additional financing, based on its operating plans at the time. Its net loss was $131.0 million in the second quarter of 2026, according to the financial results statement. In the prospectus, it said it intended to use the proceeds for "advancing our current preclinical and clinical programs." Other uses include developing its technology platform and extending its funding runway, as well as strategic investments and acquisitions and general corporate purposes.

Alongside the financing, Recursion announced that Sanofi had exercised its option on an immunology drug candidate under the companies' collaboration, according to the partnership statement filed with the SEC. The option exercise triggered a $10 million milestone payment to Recursion. This brought total upfront and milestone payments under the collaboration to $144 million as of the option exercise announcement. Recursion remains eligible for more than $300 million in additional milestone payments for this program, as well as sales royalties contingent on successful development and commercialization. The candidate was added to Sanofi's development portfolio, with Sanofi funding and leading subsequent development and commercialization, according to the partnership statement.

In its clinical program update, Recursion announced Phase 1b/2 results from a study of its drug REC-4881 in patients with familial adenomatous polyposis. The median reduction in polyp burden was 47% after 12 weeks of treatment, according to the business update statement filed with the SEC. The company had previously announced a median reduction of 43% in a cohort of 12 patients. It described the latest result as "consistent with the previously reported 43%" in its comparison with that cohort's results. In an assessment of upper gastrointestinal polyps, the median reduction in burden was 55%, according to the clinical update accompanying the offering.

The business update also included preliminary data for REC-1245 from the Phase 1 dose-escalation portion of the DAHLIA study. Recursion said the disease control rate was 91.7% in the group receiving doses of at least 45 mg. This represented disease control in 11 of 12 evaluable patients at those doses, according to the company statement. In the safety assessment, 26.7% of patients experienced treatment-related adverse events of Grade 3 or higher. The safety assessment covered all doses in the study, according to Recursion's SEC disclosure.

The prospectus anticipated delivery of the shares against payment in New York on or about October 16, 2026, according to the settlement date set by the underwriters. On clinical development, the company plans to present additional data from the polyp drug study on Monday, November 2. The presentation will take place at the annual meeting of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, according to the business update. Recursion aims to initiate a registrational trial of the drug in the second half of 2027, subject to the outcome of discussions with the U.S. Food and Drug Administration. For the immunology candidate optioned by Sanofi, the companies expect Phase 1 trials to begin in 2027 as part of its development plan.